Silence Therapeutics Plc, which is developing RNA-based therapeutics, has appointed Annalisa Jenkins as non-executive chair of its board of directors. Dr Jenkins is chief executive of Dimension Therapeutics Inc, a gene therapy company located in Cambridge, Massachusetts, US. Dimension is in the process of being acquired by Ultragenyx Pharmaceutical Inc. Dr Jenkins graduated in medicine from St Bartholomew’s Hospital in London and trained in cardiovascular medicine in the National Health Service. She began her career as a medical officer with the British Royal Navy.
Silence Therapeutics announced the appointment on 16 October 2017.
Copyright 2017 Evernow Publishing Ltd